IP Library Granted Patent US 8,303,993
Granted Patent B2
US 8,303,993 · App. 11/159,482 · Granted Nov 6, 2012

Methods of applying a biological composition to an individual

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,303,993
App. No.
11/159,482
Granted
Nov 6, 2012
Kind
B2
Abstract

The present relates to an autologous bioadhesive sealant composition, or fibrin glue prepared by a two-phase method, wherein all of the blood components for the bioadhesive sealant are derived from a patient to whom the bioadhesive sealant will be applied. A platelet rich plasma and a platelet poor plasma are formed by centrifuging a quantity of anticoagulated whole blood that was previously drawn from the patient. In one embodiment the platelet rich plasma is divided into two portions. In phase one, a compound that reverses the effect of the anticoagulant is added to the first portion and a clot is allowed to form. The clot is then triturated, and the resulting, serum containing autologous thrombin is collected. In phase two, the serum obtained from phase one is mixed with the second portion of the-platelet rich plasma to form the bioadhesive sealant of the invention.

Claims (21)

1. A method of producing a biological composition consisting of:

removing blood from an individual to whom the biological composition is intended to be applied;

centrifuging the blood to separate the blood into portions of plasma wherein the blood contains at least one of the following: a calcium chelating agent and a heparin;

obtaining thrombin from at least one portion of plasma, wherein the step of obtaining thrombin from the at least one portion of plasma comprises activation of at least a portion of the coagulation pathway;

adding a fibrinogen to at least another portion of plasma;

adding an additional agent to the at least another portion of plasma, wherein the additional agent has a biological activity;

wherein the additional agent is selected from the group consisting of analgesic compounds, antibacterial compounds, antibiotics, antifungal compounds, anti-inflammatories, antiparasitic compounds, antiviral compounds, enzymes, enzyme inhibitors, glycoproteins, growth factors, hormones, steroids, glucocorticosteroids, immunomodulators, immunoglobulins, minerals, neuroleptics, peptides, lipoproteins, tumoricidal compounds, tumorstatic compounds, toxins, vitamins, antibacterial compounds, bacteriocidal compounds and bacteriostatic compounds;

wherein the at least one portion of plasma and at least another portion of plasma are platelet rich plasma portions;

combining a defined portion of the obtained thrombin with the at least another portion of plasma, wherein prior to combining the defined portion of the obtained thrombin into the at least another portion of plasma, the fibrinogen is added into the at least another portion of plasma;

producing the biological composition as a result of the combining;

wherein the formation time of the biological composition is dependent on the defined volume of the obtained thrombin combined with the at least another portion of plasma such that the more defined volume is added the quicker the formation time.

2. The method of claim 1 , wherein the calcium chelating agent is citrate.

3. The method of claim 1 wherein the activation of at least a portion of the coagulation pathway includes adding a chemical agent to the at least one portion of plasma; and forming the thrombin within the at least one portion of plasma, wherein the chemical agent participates in the formation of the thrombin.

4. The method of claim 3 wherein the chemical agent is calcium ions.

5. The method of claim 1 , wherein the activation of at least a portion of the coagulation pathway includes placing the at least one portion of plasma in a container comprising a surface that activates blood coagulation prior to obtaining thrombin from the at least one portion of plasma.

6. The method of claim 1 wherein the activation of at least a portion of the coagulation pathway includes placing the at least one portion of plasma in a container comprising glass prior to obtaining thrombin from the at least one portion of plasma.

7. A method comprising:

applying to the individual the biological composition produced according to claim 1 .

8. The method of claim 7 wherein the step of applying the biological composition to the individual results in a barrier against loss of blood from a vessel.

9. The method of claim 8 wherein the step of applying the biological composition to the individual includes applying the biological composition to a needle hole.

10. The method of claim 1 wherein the fibrinogen is obtained from the individual to whom the biological composition is intended to be applied.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Oct 18, 2023
From: TWIN BROOK CAPITAL PARTNERS, LLC
To: ISTO TECHNOLOGIES II, LLC
Reel/Frame 065269/0604 →
SECURITY INTEREST Recorded Aug 29, 2016
From: ARTERIOCYTE MEDICAL SYSTEMS, INC.
To: TWIN BROOK CAPITAL PARTNERS, LLC, AS AGENT
Reel/Frame 039567/0894 →
RELEASE OF SECURITY INTEREST Recorded Apr 7, 2016
From: COMERICA BANK
To: ARTERIOCYTE MEDICAL SYSTEMS MANUFACTURING OF MASSACHUSETTS INCORPORATED
Reel/Frame 038381/0895 →
RELEASE OF SECURITY INTEREST Recorded Mar 28, 2016
From: ESCALATE CAPITAL PARTNERS SBIC I, L.P.
To: ARTERIOCYTE MEDICAL SYSTEMS, INC.
Reel/Frame 038113/0976 →
SECURITY INTEREST Recorded Nov 5, 2014
From: ARTERIOCYTE MEDICAL SYSTEMS, INC.
To: COMERICA BANK
Reel/Frame 034170/0303 →
SECURITY INTEREST Recorded Mar 27, 2014
From: ARTERIOCYTE MEDICAL SYSTEMS, INC.
To: ESCALATE CAPITAL PARTNERS SBIC I, L.P.
Reel/Frame 032538/0560 →